BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 16412247)

  • 1. Latency: the hidden HIV-1 challenge.
    Marcello A
    Retrovirology; 2006 Jan; 3():7. PubMed ID: 16412247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
    Chun TW; Carruth L; Finzi D; Shen X; DiGiuseppe JA; Taylor H; Hermankova M; Chadwick K; Margolick J; Quinn TC; Kuo YH; Brookmeyer R; Zeiger MA; Barditch-Crovo P; Siliciano RF
    Nature; 1997 May; 387(6629):183-8. PubMed ID: 9144289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy.
    Ikeda T; Shibata J; Yoshimura K; Koito A; Matsushita S
    J Infect Dis; 2007 Mar; 195(5):716-25. PubMed ID: 17262715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies.
    Quivy V; De Walque S; Van Lint C
    Subcell Biochem; 2007; 41():371-96. PubMed ID: 17484137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gradual shutdown of virus production resulting in latency is the norm during the chronic phase of human immunodeficiency virus replication and differential rates and mechanisms of shutdown are determined by viral sequences.
    Li XD; Moore B; Cloyd MW
    Virology; 1996 Nov; 225(1):196-212. PubMed ID: 8918547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of HIV-1 proviral latency.
    Bisgrove D; Lewinski M; Bushman F; Verdin E
    Expert Rev Anti Infect Ther; 2005 Oct; 3(5):805-14. PubMed ID: 16207172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes.
    Redel L; Le Douce V; Cherrier T; Marban C; Janossy A; Aunis D; Van Lint C; Rohr O; Schwartz C
    J Leukoc Biol; 2010 Apr; 87(4):575-88. PubMed ID: 19801499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hidden HIV reservoirs: will eradication of the virus be possible?
    Gomez E
    Newsline People AIDS Coalit N Y; 1998 Mar; ():18-9. PubMed ID: 11367451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 dynamics in vivo: implications for therapy.
    Simon V; Ho DD
    Nat Rev Microbiol; 2003 Dec; 1(3):181-90. PubMed ID: 15035022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals.
    Trono D; Van Lint C; Rouzioux C; Verdin E; Barré-Sinoussi F; Chun TW; Chomont N
    Science; 2010 Jul; 329(5988):174-80. PubMed ID: 20616270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
    Marcello A; Giacca M
    Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
    [No Abstract]   [Full Text] [Related]  

  • 13. [Molecular basis of HIV-1 latency - part I: physiology of HIV-1 latency].
    Schwartz C; Le Douce V; Cherrier T; Redel L; Marban C; Aunis D; Rohr O
    Med Sci (Paris); 2010 Feb; 26(2):159-63. PubMed ID: 20188047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 latency in actively dividing human T cell lines.
    Jeeninga RE; Westerhout EM; van Gerven ML; Berkhout B
    Retrovirology; 2008 Apr; 5():37. PubMed ID: 18439275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication.
    Pomerantz RJ
    Clin Infect Dis; 2002 Jan; 34(1):91-7. PubMed ID: 11731950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.
    Kaiser P; Joos B; Niederöst B; Weber R; Günthard HF; Fischer M
    J Virol; 2007 Sep; 81(18):9693-706. PubMed ID: 17609262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 latency and eradication of long-term viral reservoirs.
    Coiras M; Lopez-Huertas MR; Alcami J
    Discov Med; 2010 Mar; 9(46):185-91. PubMed ID: 20350483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.
    Saksena NK; Potter SJ
    AIDS Rev; 2003; 5(1):3-18. PubMed ID: 12875103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells.
    Thibault S; Imbeault M; Tardif MR; Tremblay MJ
    Virology; 2009 Jun; 389(1-2):20-5. PubMed ID: 19447460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.